IRCCS-A.O.U. San Martino, Genoa, Italy.
Allergy/Pulmonary Rehabilitation, ICP, Milan, Italy.
J Biol Regul Homeost Agents. 2013 Oct-Dec;27(4):1053-7.
Allergic patients frequently suffer from infections. Allergen immunotherapy (AIT) usually improves respiratory symptoms, mainly in allergic rhinitis (AR). This study was aimed at evaluating the possible impact of AIT on extra-allergic outcomes in a cohort of Italian children with respiratory allergy patients. The study was performed on 77 children (43 males, mean age 10.5 years) with AR. The kind and the number of prescribed allergen extracts, type of diagnosis, severity of symptoms, and use of drugs were evaluated at baseline and after 2 year AIT. Globally 40 patients were treated with AIT, the remaining 37 children served as control. AIT-treated children had lower symptoms, drug use, and less severe extra-allergic surrogate markers of infection in comparison with children untreated with AIT. In conclusion, this study provides the first evidence that 2-year SLIT is able of exerting an adjunctive anti-allergic activity in AR children.
过敏患者常患有感染症。变应原免疫疗法（AIT）通常可改善呼吸道症状，主要是变应性鼻炎（AR）。本研究旨在评估意大利一组呼吸道过敏患者中，AIT 对非变应性结果的可能影响。该研究共纳入 77 名儿童（男 43 名，平均年龄 10.5 岁），患有 AR。在基线和 AIT 治疗 2 年后，评估了规定的变应原提取物的种类和数量、诊断类型、症状严重程度和药物使用情况。总体而言，有 40 名患者接受了 AIT 治疗，其余 37 名儿童作为对照。与未接受 AIT 治疗的儿童相比，接受 AIT 治疗的儿童症状、药物使用和感染的非变应性替代标志物严重程度较低。总之，本研究首次提供了证据表明，2 年 SLIT 能够在 AR 儿童中发挥辅助抗过敏作用。
